1.Conceptualizing a Personalized Care Pathway for Parkinson’s Disease Using Wearable Sensors in Muslim Patients: The Ramadan Regime
Vinod METTA ; Huzaifa IBRAHIM ; Haidar DAFSARI ; Rajinder K. DHAMIJA ; Hani T. S. BENAMER ; Tom LONEY ; Mishal Abu AL-MELH ; Hasna HUSSAIN ; Afsal NALAREKTTIL ; Guy CHUNG-FAYE ; Gloria TANJUNG ; Bushra ALBLOOSHI ; Shaikha ALMAZROUEI ; Bassam DARWISH ; Mohamed Al MHEIRI ; Mohamed ELMAHDY ; Rukmini MRIDULA ; Sai Sampath KUMAR ; Vinay GOYAL ; Karolina POPŁAWSKA-DOMASZEWICZ ; Cristian Falup PECURARIU ; Prashanth KUKLE ; Jacob CHACKO ; Rupam BORGOHAIN ; Kallol Ray CHAUDHURI
Journal of Movement Disorders 2026;19(1):39-48
Objective:
Parkinson’s disease (PD) affects approximately 2% of individuals over the age of 60. With more than two billion Muslims observing Ramadan, individuals with PD encounter specific challenges, such as deteriorating motor skills, sleep disturbances, and an increased risk of falls during fasting.
Methods:
Our study focused on 75 patients with idiopathic PD divided into two groups: the Ramadan Regime group, which consisted of 50 patients whose medication was adjusted to twice daily at Suhoor and Iftar, and the Nontreatment group, which included 25 patients who abstained from medication for religious reasons. Both groups were instructed to wear a Parkinson’s KinetiGraph (PKG) wrist device.
Results:
The study findings revealed that motor function worsened in the Nontreatment group (p<0.001) but improved in the Ramadan Regime group (p=0.007). Daytime sleepiness also significantly increased in the Nontreatment group (p<0.001).
Conclusion
Overall, the findings suggest that the Ramadan regime significantly enhances patient health and quality of life.
2.Association of Helicobacter pylori with Parkinson's Disease.
Kandadai Rukmini MRIDULA ; Rupam BORGOHAIN ; Vupparalli CHANDRASEKHAR REDDY ; Venkata Chandrasekhar Srinivasarao BANDARU ; Turaga SURYAPRABHA
Journal of Clinical Neurology 2017;13(2):181-186
BACKGROUND AND PURPOSE: Parkinson's disease (PD) is a major neurological disorder that requires lifelong treatment, and the combined presence of Helicobacter pylori (H. pylori) infection can increase the required anti-PD medications. We aim to investigate the effect of H. pylori infection in Indian PD patients. METHODS: We prospectively recruited 36 PD patients from December 2007 to January 2011. All patients underwent a detailed neurological evaluation and serological examination for H. pylori infection. Seropositive and seronegative patients were considered to be the cases and controls, respectively. All patients who were seropositive received triple therapy for 2 weeks. Outcome measures of the mean ‘off’ Unified Parkinson's Disease Rating Scale (UPDRS)-III score, mean ‘on’ UPDRS-III score, mean onset time, mean ‘on’ duration, and mean daily ‘on’ time were measured at baseline and at a 3-week follow-up. RESULTS: H. pylori-IgG positivity was present in 18 (50%) PD patients. The prevalence of men (72.2% vs. 33.3%), mean duration of disease (13.8 vs. 12.5) and mean levodopa equivalent daily dose (824 mg vs. 707 mg) were significantly higher among H. pylori positive patients than in controls (p<0.0001). Controls had a significantly longer ‘on’ duration and daily ‘on’ time, and better ‘on’ UPDRS-III scores. Seropositive patients took a significantly longer time to turn ‘on’ after a levodopa challenge. At the 3-week follow-up, H. pylori eradication significantly improved the mean ‘on’ UPDRS-III score, onset time, ‘on’ duration, and daily ‘on’ time. CONCLUSIONS: H. pylori infection was present in 50% of Indian PD patients. H. pylori seropositivity was associated with a poor response to levodopa and increased medication usage, while eradication therapy was associated with better patient outcomes.
Follow-Up Studies
;
Helicobacter pylori*
;
Helicobacter*
;
Humans
;
Levodopa
;
Male
;
Nervous System Diseases
;
Outcome Assessment (Health Care)
;
Parkinson Disease*
;
Prevalence
;
Prospective Studies
3.Fulminant Subacute Sclerosing Panencephalitis Presenting with Acute Ataxia and Hemiparesis in a 15-Year-Old Boy.
Rukmini Mridula KANDADAI ; Praveen YADA ; Megha S UPPIN ; Shaik Afshan JABEEN ; Ajith CHERIAN ; Meena Angamuthu KANIKANNAN ; Rupam BORGOHAIN ; Sundaram CHALLA
Journal of Clinical Neurology 2014;10(4):354-357
BACKGROUND: Subacute sclerosing panencephalitis (SSPE) is a delayed and fatal manifestation of measles infection. Fulminant SSPE is a rare presentation in which the disease progresses to death over a period of 6 months. The clinical features are atypical and can be misleading. CASE REPORT: We report herein a teenage boy who presented with acute-onset gait ataxia followed by right hemiparesis that evolved over 1 month, with left-hemispheric, delta-range slowing on the electroencephalogram (EEG). Magnetic resonance imaging disclosed multiple white-matter hyperintensities, suggesting a diagnosis of acute disseminated encephalomyelitis. He received intravenous steroids, and within 4 days of hospital admission he developed unilateral slow myoclonic jerks. Repeat EEG revealed Rademecker complexes, pathognomonic of SSPE, and an elevated titer of IgG antimeasles antibodies was detected in his cerebrospinal fluid. The disease progressed rapidly and the patient succumbed within 15 days of hospitalization. The diagnosis of SSPE was confirmed by autopsy. CONCLUSIONS: This case illustrates the difficulty of recognizing fulminant SSPE when it manifests with asymmetric clinical and EEG abnormalities.
Adolescent*
;
Antibodies
;
Ataxia*
;
Autopsy
;
Cerebrospinal Fluid
;
Diagnosis
;
Electroencephalography
;
Encephalomyelitis, Acute Disseminated
;
Gait Ataxia
;
Hospitalization
;
Humans
;
Immunoglobulin G
;
Magnetic Resonance Imaging
;
Male
;
Measles
;
Myoclonus
;
Paresis*
;
Steroids
;
Subacute Sclerosing Panencephalitis*
4.Serum 25-Hydroxyvitamin D Deficiency in Ischemic Stroke and Subtypes in Indian Patients.
Jaydip Ray CHAUDHURI ; K Rukmini MRIDULA ; Suvarna ALLADI ; A ANAMIKA ; M UMAMAHESH ; Banda BALARAJU ; A SWATH ; V C S Srinivasarao BANDARU
Journal of Stroke 2014;16(1):44-50
BACKGROUND AND PURPOSE: Vitamin D deficiency is common across all age groups and may contribute to cardiovascular diseases. Serum 25-hydroxyvitamin D deficiency causing ischemic stroke has been documented in recent reports. AIM: To investigate the association of serum 25-hydroxyvitamin D deficiency with ischemic stroke and subtypes. METHODS: We recruited 250 consecutive ischemic stroke patients and 250 age and sex matched controls attending the Department of Neurology, at Yashoda hospital, Hyderabad, India, from January 2011 to December 2012. All ischemic stroke patients underwent stroke subtyping. We measured 25-hydroxyvitamin D by chemiluminescence test, serum calcium, phosphorus, alkaline phosphatase, and C-reactive protein (CRP) in cases and controls. RESULTS: Out of 250 stroke patients, 190 (76%) were men and mean age was 58.4+/-11.1 years (age range-26-89 years). 25-hydroxyvitamin D deficiency was observed in 122 (48.8%) stroke patients and 79 (31.6%) controls (P=0.001). Among stroke patients, serum 25-hydroxyvitamin D deficiency was found in 54.9% (50/91) of patients with large artery atherosclerosis, 54% (20/37) in cardioembolic stroke, 44.4% (20/45) in small artery diseases, 42.8% (15/35) in stroke of other determined etiology and 40.4% (17/42) in stroke of un-determined etiology. Multiple logistic regression analysis showed an independent association of 25-hydroxyvitamin D deficiency with ischemic stroke (odds ratio: 1.6; 95% CI 1.2-2.8). The association was strongest with large artery atherosclerosis (odds ratio: 2.4; 95% CI 1.6-3.5) and cardioembolic stroke (odds ratio: 2.0; 95% CI 1.0-3.2). CONCLUSIONS: We found that 25-hydroxyvitamin D deficiency had an independent association with ischemic stroke. The association was established in large artery arthrosclerosis and cardioembolic stroke.
Alkaline Phosphatase
;
Arteries
;
Atherosclerosis
;
C-Reactive Protein
;
Calcium
;
Cardiovascular Diseases
;
Humans
;
India
;
Logistic Models
;
Luminescence
;
Male
;
Neurology
;
Phosphorus
;
Stroke*
;
Vitamin D Deficiency
5.Clinical outcome of Guillain-Barré syndrome with various treatment methods and cost effectiveness: A study from tertiary care center in South India: Yashoda GBS Registry
Jaydip Ray Chaudhuri ; Suvarna Alladi ; K Rukmini Mridula ; Demudu Babu Boddu ; MV Rao ; C Hemanth ; V Dhanalaxmi ; J Mayurnath Reddy ; S Manimala Rao, Banda Balaraju ; Srinivasarao Bandaru
Neurology Asia 2014;19(3):263-270
Back ground and Objective: Both plasmapheresis and intra venous immunoglobulin (IVIG) are effective
for Guillain-Barré syndrome (GBS) but differ in cost and ease of administration. The aim of this study
was to evaluate and compare clinical outcome after treatment with IVIg and plasmapheresis in patients
with various GBS subtypes and assess their cost effectiveness. Methods: Thirty seven consecutive
GBS patients, recruited from May 2008 to September 2012, from Department of Neurology, Yashoda
hospital Hyderabad, underwent detailed clinical and electrophysiological assessment. Patients randomly
received either IVIG or plasmapheresis. Outcome was measured using change in mean motor power
and Hughes grade at discharge. Effectiveness and duration of hospital stay was compared with cost
effectiveness of both therapies. Results: Out of 37 patients; men were 23 (62.1%), mean age was
42.3 +14.1 years. Electro physiologically acute inflammatory demyelinating neuropathy (AIDP) was
most common (56.7%). Nineteen patients (51.3%) received IVIG and plasmapheresis was done in 18
(48.6%). Cost of plasmapheresis was significantly lower (mean USD 2,584.5 versus USD 4,385.3)
(p=0.01). At discharge, significant and similar improvement was noted in both groups although
duration of hospital stay was longer in plasmapheresis group Three patients (2 in plasmapheresis and
one in IVIG group) died.
Conclusion: In developing countries, plasmapheresis may be a better option in treatment of GBS.

Result Analysis
Print
Save
E-mail